Ainos, Inc. Annual Report - How They Did This Year

I’ve put together a plain-English guide to help you understand how Ainos, Inc. performed this year. My goal is to turn complex filing information into something that makes sense, so you can decide if this company fits your investment goals.

1. What does this company do?

Ainos combines high-tech sensors with medical treatments:

• AI Nose (Ainos Core): This is their "smell-tech." They use sensors and AI to turn scents into data. They’ve moved from medical testing into industrial settings—specifically semiconductor plants. Their sensors monitor air quality, detect chemical leaks, and spot equipment issues in real-time.
• VELDONA®: This is their medical arm. They use low-dose interferon alpha to create oral treatments for immune-related conditions. They are currently testing treatments for human oral warts and a condition in cats called feline chronic gingivostomatitis.

2. How are they performing?

The company is moving from research to selling its products through pilot programs.

• The Shift: In fiscal year 2025, Ainos pivoted toward industrial partnerships to stabilize cash. They signed a multi-year deal with a semiconductor manufacturer in Taiwan. They are moving toward a subscription model for both software and hardware to create steady, recurring income rather than relying on one-time sales.
• The Data Loop: Every AI Nose deployment feeds their database. By training their software on real-world factory data, Ainos hopes to build a competitive advantage that is difficult for others to copy.

3. Financial health: The "Burn"

Ainos is in a growth phase where it spends much more cash than it earns.

• Revenue: For the year ending March 31, 2025, the company earned about $123,000, mostly from AI Nose pilot programs. However, they reported an operating loss of about $14.1 million. This shows a massive gap between their current sales and the high costs of research and clinical trials.
• Dilution: To keep running, the company relies on selling more shares. They executed a 1-for-10 reverse stock split in 2023 and a 1-for-20 split in 2024 to stay on the Nasdaq. For you, this means the company frequently issues more shares to raise cash, which reduces your ownership percentage. They burn through about $1.1 million in cash every month.

4. Major wins and risks

• The Win: Ainos uses an "asset-light" model. By outsourcing production to manufacturers in Taiwan, they avoid the high cost of building their own factories. This allows them to scale quickly if demand grows.
• The Risk: The company faces big regulatory and concentration risks. None of their VELDONA® products have FDA approval, so they have no pharmaceutical sales. Also, their revenue is concentrated; losing their main semiconductor partner would wipe out their current recurring income. If their share price stays low, they may struggle to raise the cash needed to reach profitability.

5. The Bottom Line

Ainos is a high-risk, speculative bet. It relies on the success of its industrial sensors and medical therapies. If they successfully make their AI Nose a standard safety feature in semiconductor plants, they could capture a profitable niche. However, with high spending and very little revenue, the company faces a constant threat of running out of cash or further diluting shareholders. This is not a stable investment; it is a venture-style play that needs major breakthroughs within the next two years to survive.

Investor Checklist:

• Watch the Cash: Keep an eye on their monthly burn rate and how often they issue new shares.
• Monitor Partnerships: Look for announcements regarding new semiconductor clients, as their current revenue depends heavily on a single partner.
• Track Regulatory Progress: Check for updates on FDA or other regulatory filings for VELDONA®, as these are necessary for the company to move into pharmaceutical sales.